Gene Therapy Market size was over USD 9.4 Billion in 2023 and is expected to reach USD 98.4 Billion by the end of 2036, witnessing around 19.8% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of gene therapy is evaluated at USD 11.2 Billion.
The market is expanding due to the rise in cancer patients and deaths associated with the disease highlighting the need for effective therapeutic alternatives. The World Health Organization predicts that there will be over 35 million new cases of cancer in 2050, up 77% over the 20 million cases expected in 2022. Furthermore, WHO anticipated that high HDI nations will see the most absolute increases in incidence, with an extra 4.8 million new cases estimated in 2050 compared to estimates for 2022.
Growth Drivers
Challenges
Base Year |
2023 |
Forecast Year |
2024–2036 |
CAGR |
19.8% |
Base Year Market Size (2023) |
USD 9.4 Billion |
Forecast Year Market Size (2036) |
USD 98.4 Billion |
Regional Scope |
|
Type (Gene Silencing, Cell Replacement, Gene Augmentation)
Gene silencing segment in the gene therapy market is estimated to cross USD 10 Billion by 2036. The segment growth can be credited to the presence of several gene therapy products that use a method of gene silencing. Silencing genes has also been shown to be a useful strategy, particularly against neurological disorders like neuromuscular illnesses.
The effectiveness and specificity of gene silencing techniques have been greatly improved by ongoing developments in gene editing technologies, including CRISPR–Cas9, RNA interference (RNAi), and antisense oligonucleotides, which often reduce a gene’s expression by at least 70% without completely eliminating it.
Therapeutic Area (Neurology, Oncology, Hepatology)
Neurology segment in the gene therapy market is estimated to register more than 7.6% growth from 2024 to 2036. The segment is growing due to the technological advancements in gene therapy. Highly specific viral vector designs, plasmid transfection, nanoparticles, polymer–mediated gene delivery, engineered microRNA, and in vivo clustered regulatory interspaced short palindromic repeats (CRISPR)–based therapeutics have been the focus of recent technological advancements for improved gene sequence delivery.
Highly common neurological and neurodevelopmental disorders, such as Parkinson's disease, Alzheimer's disease, and autism spectrum disorder, can be effectively treated with these cutting–edge techniques. According to Alzheimer’s Disease International Organization, in 2020, there were about 55 million dementia patients worldwide. By 2050, there will be 139 million people on the planet, having nearly doubled every 20 years to 78 million in 2030. Therefore, the growing cases of such diseases are propelling the growth of the segment.
Route of Administration (Intravenous, Others)
By the end of 2036, intravenous segment is estimated to capture gene therapy market share of around 60%. The primary driver of the segment's dominance is the substantial pipeline of IV candidates and the high number of approved medications. The least complex and intrusive technique for cardiac gene transfer that is currently available is intravenous injection. Injection into the tail vein of rodents successfully expresses the cardiac gene. Throughout the projected period, this segment is likewise anticipated to become the most lucrative.
Our in–depth analysis of the market includes the following segments:
Type |
|
Vector |
|
Therapeutic Area |
|
Delivery Method |
|
Route of Administration |
|
North America Market Statistics
North America region in gene therapy market is poised to account for more than 37% revenue share by the end of 2036. The market growth in the region is also expected on account of the presence of extremely sophisticated infrastructure in hospitals, and the availability of cutting–edge technologies, such as the diagnostics needed to determine a patient's eligibility for gene therapy.
The United States has a strong gene therapy pipeline at the moment, with several promising treatments at different phases of research. Numerous of these treatments target uncommon genetic conditions such as hemophilia, choroideremia, Duchenne muscular dystrophy, and spinal muscular atrophy. According to the Centers for Disease Control and Prevention study, up to 33,000 men in the US are expected to have hemophilia A, based on data gathered on patients getting care in federally funded hemophilia treatment centers between 2012 and 2018. Additionally, treatments that can more precisely target particular genetic abnormalities are being developed using gene editing technologies like CRISPR–Cas9.
The market in Canada is being driven by the government's increased investments and the rising incidence of specific diseases. Also, growing investment in healthcare is accelerating the market growth in the region. According to the Canadian Medical Association, it was projected that Canada will spend USD 344 billion on health care, or USD 8,740 per person in 2023.
European Market Analysis
Gene therapy market size for Europe region is projected to cross USD 19 Billion by the end of 2036 during the forecast period due to the region’s sizable population, unmet medical requirements, and the need for cutting–edge solutions to address uncommon but more common diseases. According to the European Commission report in 2023, the EU's total population increased by 4%, from 429 million to 447 million, between 2001 and 2020. The European Union (EU) was home to 446.7 million people as of January 2022.
The surging investments by various big companies and governments in the United Kingdom are influencing the growth of the market in the region. According to the UK Government, The National Health Service (NHS) offers a research support service to sponsors and contract research organizations (CROs) with an annual investment of USD 1.09 billion. It is home to sixty cell and gene therapy experiments at the moment.
Due to significant expenditures made by both the public and commercial sectors, which have accelerated the growth of the nation's cell and gene therapy market, Germany stands at the forefront of this field. Germany is now engaged in the development and testing of novel cell and gene therapy medications that provide significant advantages to patients.
The introduction of new medicines, technologically sophisticated product launches, regulatory approvals, acquisitions, and joint ventures with other businesses are the activities of major players in the global market. These tactics are probably going to encourage the worldwide market's expansion.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?